Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Matsui · SciRah

Researcher profile · Semantic Scholar

J. Matsui

Share profile

J. Matsui — researcher profile on SciRah

h-index: 36
Works: 137
Citations: 8,788

Most-cited papers

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
O. Tohyama, J. Matsui, Kotaro Kodama, N. Hata-Sugi +5 more
2014Journal of Thyroid Research436 citations Open access
Semantic Scholar
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato, Kimiyo Tabata, Takayuki Kimura, Ayako Yachie-Kinoshita +12 more
2019PLoS ONE434 citations Open access
Semantic Scholar
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto, J. Matsui, T. Matsushima, H. Obaishi +20 more
2014Vascular Cell428 citations Open access
Semantic Scholar
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
Taku Yoshida, Y. Ozawa, Takayuki Kimura, Yoshiaki Sato +7 more
2014British Journal of Cancer339 citations Open access
Semantic Scholar
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
Takayuki Kimura, Yu Kato, Y. Ozawa, Kotaro Kodama +9 more
2018Cancer Science313 citations Open access
Semantic Scholar
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models
Y. Funahashi, Kiyoshi Okamoto, Y. Adachi, T. Semba +14 more
2014Cancer Science255 citations Open access
Semantic Scholar
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
M. Matsuki, Taisuke Hoshi, Yuji Yamamoto, M. Ikemori-Kawada +3 more
2018Cancer Medicine248 citations Open access
Semantic Scholar
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Kiyoshi Okamoto, M. Ikemori-Kawada, A. Jestel, Konstanze von König +5 more
2015ACS Medicinal Chemistry Letters239 citations Open access
Semantic Scholar
Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers
Felix Sanchez-Garcia, P. Villagrasa, J. Matsui, Dylan Kotliar +8 more
2014Cell98 citations Open access
Semantic Scholar
Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Taisuke Hoshi, Saori Watanabe Miyano, Hideki Watanabe, Regina Mikie Kanada Sonobe +5 more
2019Biochemical and Biophysical Research Communications - BBRC66 citations Open access
Semantic Scholar
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
M. Matsuki, Y. Adachi, Y. Ozawa, Takayuki Kimura +7 more
2017Cancer Science65 citations Open access
Semantic Scholar
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
S. Kawano, A. Grassian, M. Tsuda, S. Knutson +13 more
2016PLoS ONE63 citations Open access
Semantic Scholar
Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models
K. Ito, S. Hamamichi, Takanori Abe, T. Akagi +8 more
2017Cancer Science59 citations Open access
Semantic Scholar
Vacuolin‐1 inhibits autophagy by impairing lysosomal maturation via PIKfyve inhibition
Osamu Sano, Ken-ichi Kazetani, M. Funata, Yasunori Fukuda +2 more
2016FEBS Letters58 citations Open access
Semantic Scholar
E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling
K. Yamada, Yusaku Hori, Satoshi Inoue, Yuji Yamamoto +29 more
2021Cancer Research54 citations
Semantic Scholar
Activated FGF2 signaling pathway in tumor vasculature is essential for acquired resistance to anti-VEGF therapy
Kenji Ichikawa, Saori Watanabe Miyano, Y. Minoshima, J. Matsui +1 more
2020Scientific Reports52 citations Open access
Semantic Scholar
Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing.
T. Sakurai, R. Davenport, Stuart Stafford, J. Grosse +12 more
2014European Journal of Pharmacology51 citations
Semantic Scholar
Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
S. Kawano, M. Asano, Y. Adachi, J. Matsui
2016Anticancer Research49 citations
Semantic Scholar
Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Y. Kamada, Nozomu Sakai, S. Sogabe, K. Ida +8 more
2017Journal of Medicinal Chemistry48 citations Open access
Semantic Scholar
Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response
Yu Kato, X. Bao, S. MacGrath, Kimiyo Tabata +5 more
201639 citations Open access
Semantic Scholar
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, Yukiko Miyajima +18 more
2016Molecular Cancer Therapeutics39 citations Open access
Semantic Scholar
Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti-angiogenesis activity in a preclinical cancer model
Youya Nakazawa, S. Kawano, J. Matsui, Y. Funahashi +4 more
2015Cancer Science37 citations Open access
Semantic Scholar
Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor
T. Nakagawa, T. Matsushima, S. Kawano, Youya Nakazawa +8 more
2014Cancer Science37 citations Open access
Semantic Scholar
Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vitro
S. Agoulnik, S. Kawano, Noel Taylor, J. Oestreicher +4 more
2014Vascular Cell37 citations Open access
Semantic Scholar
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Yusaku Hori, K. Ito, S. Hamamichi, Y. Ozawa +3 more
2017Anticancer Research33 citations Open access
Semantic Scholar
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms
M. Asano, J. Matsui, M. Towle, Jiayi Wu +5 more
2018Anticancer Research30 citations Open access
Semantic Scholar
A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet-Induced Obese C57BL/6J Mice
H. Yashiro, Shuichi Takagahara, Yumiko Okano Tamura, Ikuo Miyahisa +4 more
2016PLoS ONE30 citations Open access
Semantic Scholar
Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models
K. Ito, S. Hamamichi, M. Asano, Yusaku Hori +5 more
2015Cancer Science27 citations Open access
Semantic Scholar
High response rate and durability driven by HLA genetic diversity in kidney cancer patients treated with the immunotherapy combination lenvatinib and pembrolizumab.
Chung-Han Lee, R. DiNatale, Diego Chowell, C. Krishna +22 more
2021Molecular Cancer Research26 citations Open access
Semantic Scholar
Feedback activation of AMPK-mediated autophagy acceleration is a key resistance mechanism against SCD1 inhibitor-induced cell growth inhibition
Akito Ono, Osamu Sano, Ken-ichi Kazetani, Takamichi Muraki +4 more
2017PLoS ONE26 citations Open access
Semantic Scholar
Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice
Rong Wang, Tadaaki Yamada, S. Arai, K. Fukuda +11 more
2019Molecular Cancer Therapeutics22 citations Open access
Semantic Scholar
Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors
Yu Kato, Kimiyo Tabata, Yusaku Hori, Sho Tachino +2 more
201519 citations
Semantic Scholar
Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma
Y. Adachi, M. Matsuki, Hideki Watanabe, Kazuma Takase +4 more
2019Cancer Investigation17 citations
Semantic Scholar
Identification and Characterization of a New Series of Ghrelin O-Acyl Transferase Inhibitors
M. Yoneyama-Hirozane, K. Deguchi, Takeshi Hirakawa, Tsuyoshi Ishii +8 more
2018SLAS discovery : advancing life sciences R & D14 citations Open access
Semantic Scholar
Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways
J. Matsui
201613 citations Open access
Semantic Scholar
Tubulin is a molecular target of the Wnt-activating chemical probe
Yasunori Fukuda, Osamu Sano, Ken-ichi Kazetani, Koji Yamamoto +2 more
2016BMC Biochemistry13 citations Open access
Semantic Scholar
Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors.
J. Fujimoto, R. Okamoto, N. Noguchi, Ryoma Hara +15 more
2017Journal of Medicinal Chemistry12 citations Open access
Semantic Scholar
T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.
Ikuo Miyahisa, Hideo Suzuki, Atsushi Mizukami, Y. Tanaka +3 more
2016ACS Medicinal Chemistry Letters11 citations Open access
Semantic Scholar
In vivo production of engineered ACE2 decoy protects lungs from SARS-CoV-2 infection
Yuta Suzuki, Takayuki Miyazaki, Yoko Ida, Tatsuya Suzuki +16 more
2025Molecular Therapy: Nucleic Acids8 citations Open access
Semantic Scholar
β-catenin/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer
Eric R. Reed, Stacy A. Jankowski, A. Spinella, V. Noonan +7 more
2023Translational Research: The Journal of Laboratory and Clinical Medicine8 citations Open access
Semantic Scholar
Inhibition of Notch4 Using Novel Neutralizing Antibodies Reduces Tumor Growth in Murine Cancer Models by Targeting the Tumor Endothelium
J. Eng, Yu Kato, Y. Adachi, B. Swaminathan +25 more
2024Cancer Research Communications7 citations Open access
Semantic Scholar
Discovery of a potent and selective Axl inhibitor in preclinical model.
Satoshi Inoue, Y. Yamane, Shuntaro Tsukamoto, H. Azuma +14 more
2021Bioorganic & Medicinal Chemistry7 citations Open access
Semantic Scholar
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.
V. Makker, A. Cohn, M. Taylor, Y. Minoshima +9 more
20186 citations
Semantic Scholar
Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
K. Yamada, Yusaku Hori, Atsumi Yamaguchi, M. Matsuki +22 more
20176 citations
Semantic Scholar
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Satoshi Inoue, Y. Yamane, Shuntaro Tsukamoto, Norio Murai +14 more
2021Bioorganic & Medicinal Chemistry Letters5 citations Open access
Semantic Scholar
Genomic biomarkers of response to lenvatinib/pembrolizumab (Len/Pembro) in patients with advanced renal cell carcinoma.
Chung-Han Lee, R. DiNatale, Diego Chowell, C. Krishna +15 more
20204 citations
Semantic Scholar
Abstract 4089: Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model
T. Semba, Kimiyo Tabata, Y. Ozawa, S. W. Miyano +2 more
2019Immunology4 citations
Semantic Scholar
Identification of Combinatorial Drugs that Synergistically Kill both Eribulin-Sensitive and Eribulin- Insensitive Tumor Cells
R. Rickles, J. Matsui, Y. Funahashi, Janine L. Steiger +2 more
20154 citations
Semantic Scholar
Phase I Biomarker Analysis Results of MORAb-202 (Farletuzumab Ecteribulin) Effects on Vascular Remodeling and Immune Modulation in Patients With Ovarian Cancer
Y. Zhang, S. Li, T. Uenaka, K. Furuuchi +12 more
2022European Journal of Cancer3 citations Open access
Semantic Scholar
Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146.
Chung-Han Lee, D. Rasco, Arpit Rao, M. Taylor +16 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Funahashi×24
Invite
Y. Funahashi — researcher profile on SciRah
K. Nomoto×12
Invite
K. Nomoto — researcher profile on SciRah
Y. Minoshima×10
Invite
Y. Minoshima — researcher profile on SciRah
Yu Kato×10
Invite
Yu Kato — researcher profile on SciRah

×10

Invite

Y. Ozawa — researcher profile on SciRah

Invite

Yusaku Hori — researcher profile on SciRah

T. Matsushima×8

Invite

T. Matsushima — researcher profile on SciRah

Invite

Y. Adachi — researcher profile on SciRah

Invite

S. Kawano — researcher profile on SciRah

Takayuki Kimura×6

Invite

Takayuki Kimura — researcher profile on SciRah

Kiyoshi Okamoto×6

Invite

Kiyoshi Okamoto — researcher profile on SciRah

Invite

Masao Iwata — researcher profile on SciRah